Evidence map›Paper›PMID 42205537›Full record

ArticleFrontiers in molecular biosciences2026

Tumor-directed evolution of VSVΔ51M produces novel viruses with enhanced antitumor efficacy.

Omar A Albaradie, Abdulaziz Molham Moglan, Yahya Marwan Samman, Fares Fayez Alsayegh, Hussam Mohsen Alharbi, Nada Almarghalani, Khulood Alotaibi, Mohammed M Jalal, Malik A Altayar, Nizar H Saeedi and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in molecular biosciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Omar A AlbaradieCollege of Medicine, King Saud bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia.
Abdulaziz Molham MoglanCollege of Medicine, King Saud bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia.
Yahya Marwan SammanCollege of Medicine, King Saud bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia.
Fares Fayez AlsayeghCollege of Medicine, King Saud bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia.
Hussam Mohsen AlharbiCollege of Medicine, King Saud bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia.
Nada AlmarghalaniKing Abdullah International Medical Research Center, Jeddah, Saudi Arabia.
Khulood AlotaibiKing Abdullah International Medical Research Center, Jeddah, Saudi Arabia.
Mohammed M JalalDepartment of Medical Laboratory Technology, Faculty of Applied Medical Sciences, University of Tabuk, Tabuk, Saudi Arabia.
Malik A AltayarDepartment of Medical Laboratory Technology, Faculty of Applied Medical Sciences, University of Tabuk, Tabuk, Saudi Arabia.
Nizar H SaeediDepartment of Medical Laboratory Technology, Faculty of Applied Medical Sciences, University of Tabuk, Tabuk, Saudi Arabia.
Hanan A NiazDepartment of Medical Laboratory Technology, Faculty of Applied Medical Sciences, University of Tabuk, Tabuk, Saudi Arabia.
Samer ZakriKing Saud bin Abdulaziz University for Health Sciences, Ministry of National Guard Health Affairs, Jeddah, Saudi Arabia.
Adnan AlmuzainiExperimental Medicine Department, King Abdullah International Medical Research Centre, Jeddah, Saudi Arabia.
Feras KabohaExperimental Medicine Department, King Abdullah International Medical Research Centre, Jeddah, Saudi Arabia.
Saleh Y AlabbasImmunology Research Program, King Abdullah International Medical Research Center, Jeddah, Saudi Arabia.
Yasmeen A AlbalawiDepartment of Biology, College of Science, Jouf University, Sakaka, Aljouf, Saudi Arabia.
Abeer AlsofyaniKing Saud bin Abdulaziz University for Health Sciences, Ministry of National Guard Health Affairs, Jeddah, Saudi Arabia.
Adrian PelinDepartment of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA, United States.
May Abdulaiz AlsaybCollege of Applied Medical Sciences, Taibah University, Almadinah Almunwarah, Saudi Arabia.
Shymaa DamfoHealth and Life Research Center, Taibah University, Almadinah Almunwarah, Saudi Arabia.
Ahmad Bakur MahmoudCollege of Applied Medical Sciences, Taibah University, Almadinah Almunwarah, Saudi Arabia.
Almohanad A AlkayyalDepartment of Medical Laboratory Technology, Faculty of Applied Medical Sciences, University of Tabuk, Tabuk, Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oncolytic virotherapy has gained enormous attention and is undergoing extensive research, specifically, the Vesicular Stomatitis Virus (VSV). VSV has been shown to provide a potential tool on which many modifications can be introduced to improve its efficacy. Here we report utilizing a modified VSV with a deletion mutation at the 51 amino acid of its matrix protein (VSVΔ51), designed to leverage the innate antiviral immunity of healthy cells through the interferon pathway. We serially passaged VSVΔ51M thirty times in B16F10 and LLC1 cell lines. Plaque purification was performed post-passaging to ensure viral homogeneity. Using an ATP release-based assay, we demonstrated that serial passaging significantly enhanced the oncolytic activity of VSVΔ51M

Indexed as

oncolytic virotherapypersonalized therapyvesicular stomatitis virusviral evolutionVSVΔ51M

Identifiers

PMID42205537
PMCPMC13202179

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.